Sample stability:
Units: U/mL
|
Reference interval: < 35 |
The sensitivity and specificity of the test depend on the cutoff level used.
Comparing ovarian carcinoma patients at diagnosis with patients with benign gynaecological diseases :
| cutoff value | sensitivity | specificity |
|---|---|---|
|
65 U/mL |
79% |
82% |
|
150 U/mL |
69% |
93% |
Uncertainty of Measurement: 6%
Principle : Electrochemiluminescence Immunoassay
Reagents: Roche Elecsys CA 125 II
Analyser: Cobas e801
Monitoring the treatment and predicting recurrence of ovarian cancer.
Not all ovarian cancers express CA 125.
CA 125 is not suitable as a screening test for use in primary diagnosis of tumours.
CA 125 concentrations of up to 60 U/mL may occur during normal menstruation.
Elevated levels may occur in other malignancies, pregnancy, or less frequently in non-malignant conditions such as liver disease, endometriosis, ovarian cysts, and peritoneal trauma (laparotomy). Gastrointestinal, bronchial and breast carcinomas are occasionally associated with elevated CA 125.
The half life of CA 125 is 5 days.
The chemical pathology team can be reached via email: chemicalpathologist@adhb.govt.nz or via Lablink (09) 307 4949 ext 22000 or 09-3078995
Emails will receive priority attention from the on-call chemical pathologist. Include the patients NHI.
After-hours: contact Lablink (Auckland City Hospital ext. 22000 or 09-3078995) or hospital operator for on duty staff after hours .
- Dr Samarina Musaad (Clinical Lead) : SamarinaM@adhb.govt.nz ext. 22402
- Dr Cam Kyle : CampbellK@adhb.govt.nz ext 22052
- Dr Weldon Chiu : WeldonC@adhb.govt.nz ext. 23427
- Dr Campbell Heron : CHeron@adhb.govt.nz ext. 23427
- Dr Sakunthala Jayasinghe Saku.Jayasinghe@adhb.govt.nz
- Dr Owen Yi WenyiYi@adhb.govt.nz